Safety is essential in every phase of clinical trials and device investigations, from pre- to post-marketing: that’s why InnoPharma safety and pharmacovigilance team members are all certified EudraVigilance users, carefully trained and dedicated to the utmost attention to timelines and details.

Through tailored programs, InnoPharma ensures to meet the strict requirements of the regulatory authorities, committees, study sites and team.

From the development of Safety Management Plans, to the Adverse Events (AEs) and Serious Adverse Events (SAEs) management and reporting, the expedited reporting of SUSAR line listing to the Competent Authorities and Ethics Committees, the timely transmission of Safety Reports and DSUR to the Regulatory Authorities, everything will be under constant control and vigilance.